IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (03-332-B (400.126))

Serial No: 10/652,791) Group Art Unit: 1635

Filed: August 29, 2003) Examiner: TBA

For: RNA Interference Mediated Inhibition of Platelet-Derived Endothelial Cell Growth Factor (ECGF1) Gene Expression Using Short Interfering Nucleic Acid (siNA)

Mail Stop: Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 1.821(f)

Sir/Madam:

The undersigned representative hereby declares that the content of the substitute electronic copies of the Sequence Listing, submitted in the above-identified application in compliance with 37 C.F.R. § 1.52(e) on Compact Disc-Recordable (CD-R) medium in duplicate (COPY 1 and COPY 2), in lieu of the paper copy under 37 C.F.R. § 1.821(c), and substitute computer readable form copy of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. §§ 1.825(b) and 1.821(e), are identical in content. The substitute sequence listing, submitted herewith, does not extend beyond the scope of the specification, and thus, does not contain new matter. The CD-R labeled "Substitute CRF of Sequence Listing submitted under 37 C.F.R. §§ 1.825(b) and 1.821(e)" contains an IBM compatible dos-text file of the sequence listing named "400.126 Sequence Listing.ST25".

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Dated: October 12, 2004

By:

Christopher P. Singer

Reg. No. #8,701

PHONE: 312-913-0001 FAX: 312-913-0002